Trials / Completed
CompletedNCT00971308
Multiple Dose Study In Treatment Naive Subjects Infected With Hepatitis C Virus
Open Label, Multiple-Dose Study to Evaluate the Antiviral Activity, Safety, Tolerability and Pharmacokinetics of BMS-824393 in Treatment Naive Subjects Infected With Hepatitis C Virus Genotype 1
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the antiviral effect following three days of dosing with BMS-824393 in chronically genotype subtype 1a and 1b Hepatitis C virus (HCV) infected subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-824393 | Capsule, Oral, 50mg, Once Daily, 3 days |
| DRUG | BMS-824393 | Capsule, Oral, 100mg, Once Daily, 3 days |
| DRUG | BMS-824393 | Capsule, Oral, 10mg, Once Daily, 3 days |
| DRUG | BMS-824393 | Capsule. Oral, 1mg, Once Daily, 3 days |
| DRUG | BMS-824393 | Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2010-08-01
- Completion
- 2010-08-01
- First posted
- 2009-09-03
- Last updated
- 2011-01-25
Locations
6 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00971308. Inclusion in this directory is not an endorsement.